U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C12H19NO2
Molecular Weight 209.2848
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BAMETHAN

SMILES

CCCCNCC(O)C1=CC=C(O)C=C1

InChI

InChIKey=RDUHXGIIUDVSHR-UHFFFAOYSA-N
InChI=1S/C12H19NO2/c1-2-3-8-13-9-12(15)10-4-6-11(14)7-5-10/h4-7,12-15H,2-3,8-9H2,1H3

HIDE SMILES / InChI

Molecular Formula C12H19NO2
Molecular Weight 209.2848
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Bamethan (butyl-sympatol or vasculat) is an adrenaline derivative developed by C. H. Boehringer Sohn. Bamethan shows a depressor action on peripheral blood vessels as a result of the peripheral vasodilating action caused by stimulation of adrenergic beta-receptor. Bamethan has been used abroad in the treatment of certain peripheral vascular and circulatory disturbances, such as vasospastic conditions, arteriosclerotic peripheral vascular disease, Raynaud's syndrome, occlusive vascular disease of the legs, the post-thrombotic syndrome, degenerative muscular disorders, and other conditions involving peripheral vascular insuffciency.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VASCULAT

Approved Use

Bamethan has been used abroad in the treatment of certain peripheral vascular and circulatory disturbances, such as vasospastic conditions, arteriosclerotic peripheral vascular disease, Raynaud's syndrome, occlusive vascular disease of the legs, the post-thrombotic syndrome, degenerative muscular disorders, and other conditions involving peripheral vascular insuffciency.
Doses

Doses

DosePopulationAdverse events​
100 mg single, oral
Studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
healthy
Health Status: healthy
Sex: M+F
Sources:
PubMed

PubMed

TitleDatePubMed
Tandem mass spectrometry with online high-flow reversed-phase extraction and normal-phase chromatography on silica columns with aqueous-organic mobile phase for quantitation of polar compounds in biological fluids.
2005
Development and validation of a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of ribavirin in human plasma and serum.
2002-06-20
The effect of bamethan on cardiovascular response.
1966-01-01

Sample Use Guides

75-100 mg
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:42:24 GMT 2025
Edited
by admin
on Wed Apr 02 09:42:24 GMT 2025
Record UNII
Y08ZFJ9TFK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VASOLAT
Preferred Name English
BAMETHAN
INN   MI   WHO-DD  
INN  
Official Name English
BENZENEMETHANOL, .ALPHA.-((BUTYLAMINO)METHYL)-4-HYDROXY-
Systematic Name English
BAMETHAN [MI]
Common Name English
Bamethan [WHO-DD]
Common Name English
bamethan [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QC04AA31
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
NCI_THESAURUS C48149
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
WHO-ATC C04AA31
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
Code System Code Type Description
RXCUI
1321
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY RxNorm
NCI_THESAURUS
C76116
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY
SMS_ID
100000088408
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY
ECHA (EC/EINECS)
223-043-9
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY
CAS
3703-79-5
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY
WIKIPEDIA
BAMETHAN
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY
EPA CompTox
DTXSID5046144
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY
PUBCHEM
2292
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY
FDA UNII
Y08ZFJ9TFK
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY
DRUG BANK
DB13206
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY
MERCK INDEX
m2217
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY Merck Index
EVMPD
SUB06096MIG
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY
DRUG CENTRAL
286
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY
INN
995
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY
MESH
C084810
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY
ChEMBL
CHEMBL1987462
Created by admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY